Cost of Revenue Comparison: Amgen Inc. vs Walgreens Boots Alliance, Inc.

Amgen vs Walgreens: A Decade of Cost Dynamics

__timestampAmgen Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 2014442200000054823000000
Thursday, January 1, 2015422700000076691000000
Friday, January 1, 2016416200000087477000000
Sunday, January 1, 2017406900000089052000000
Monday, January 1, 20184101000000100745000000
Tuesday, January 1, 2019435600000091915000000
Wednesday, January 1, 2020615900000095905000000
Friday, January 1, 20216454000000104442000000
Saturday, January 1, 20226406000000104437000000
Sunday, January 1, 20238415000000112009000000
Monday, January 1, 202412858000000121134000000
Loading chart...

Unlocking the unknown

Cost of Revenue: A Tale of Two Giants

In the ever-evolving landscape of the pharmaceutical and retail sectors, Amgen Inc. and Walgreens Boots Alliance, Inc. stand as titans. Over the past decade, these companies have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, Walgreens Boots Alliance consistently reported a cost of revenue that was approximately 10 times higher than Amgen's. This stark difference highlights the scale and operational demands of a global retail giant compared to a leading biotech firm.

A Decade of Change

Amgen's cost of revenue saw a steady increase, peaking in 2023 with a 100% rise from its 2014 figures. In contrast, Walgreens Boots Alliance experienced a more volatile journey, with a notable 104% increase from 2014 to 2024. The missing data for Amgen in 2024 suggests a potential shift or anomaly, inviting further exploration into its financial strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025